Browse by Hotbed/Location
Filter News
Found 592,117 articles
-
BioSpace Hotbed maps have been a life sciences industry staple for over 30 years. Today the program features eight regional Hotbed Maps and the NextGen Bio Map which highlights some of the industry’s most promising startups.
-
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
-
Final Ruling on Medicare Most-Favored-Nation Drug Pricing Set for Federal Register Publication
11/26/2020
The interim final rule aligns payment for Medicare Part B therapeutics with international prices and removes incentives for physicians to prescribe more expensive drugs and biologics. -
Vivera Pharmaceuticals Announces $440 Million in Backing by JR Dallas Wealth Management
11/26/2020
Vivera Pharmaceuticals and Burkhan World today announce financial backing by JR Dallas Wealth Management in support of Vivera's global growth strategies. This ongoing partnership will provide financial services – including debt and equity backing – for the purchase and distribution of Vivera's innovative testing and expansi
-
CB2 Insights Announces Results of Special Shareholders Meeting and Schedule for Q3 2020 Earnings Call
11/26/2020
CB2 receives majority shareholder approval for all 3 resolutions proposed. CB2 will release Q3 2020 financial results and MD&A after market close on Monday November 30 th , 2020 and subsequently host its earnings call on Tuesday December 1, 2020 at 9 am EDT. CB2 will begin trading under its new name, Skylight Health Group Inc., and new ticker symbol “SHG” on the Canadian Securities Exchange on Monday November 30, 2020. TORONTO, Nov. 25, 2020 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII
-
FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma
11/26/2020
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. Food and Drug Administration (“FDA”) has approved DANYELZA (naxitamab-gqgk) 40mg/10ml. DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CS
-
908 Devices Announces Filing Of Registration For Proposed Initial Public Offering
11/26/2020
908 Devices, a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. 908 Devices int
-
Egle Therapeutics Identifies First Novel Regulatory T-cell Targets in Research Alliance with Takeda
11/26/2020
Egle Therapeutics SAS, an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases, announces that it has achieved the first milestone in its strategic research alliance with Takeda Pharmaceutical Company Limited.
-
MaaT Pharma to Provide Data Update for Lead Microbiome Biotherapeutic in Oral Presentation at 62nd American Society of Hematology (ASH) Annual Meeting
11/26/2020
Treatment of 29 acute gastrointestinal Graft-versus-Host-Disease patients with full-ecosystem microbiome restoration biotherapeutic MaaT013 reported safe, demonstrating positive impact
-
BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10
11/26/2020
Cantargia AB and BioInvent International AB, announced that BioInvent has been contracted as manufacturer of Cantargia's antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis.
-
IRRAS Announces Expansion of IRRAflow Launch to The Netherlands
11/26/2020
IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, announced an exclusive distribution agreement with KM Innovations BV, a leading distributor of world-class neurosurgical medical devices and technologies in The Netherlands.
-
Gustaf Salford appointed Elekta CEO by Board of Directors
11/26/2020
Elekta announced that Gustaf Salford has been appointed to the role of President and CEO, effective immediately.
-
Interim report, May-October 2020/21
11/26/2020
In Elekta's second quarter, we managed to perform better than the overall radiotherapy market both in terms of orders and revenue despite continuous challenging circumstances.
-
Vifor Pharma supports Iron Deficiency Day 2020 to highlight global impact on health and gender inequality
11/26/2020
Vifor Pharma is marking the sixth anniversary of Iron Deficiency Day, focused on raising international awareness of the serious health impact of iron deficiency and iron deficiency anemia1 – with the support of international organizations including Global Heart Hub, Anaemia Community, the Heart Failure Policy Network and Croí, the West of Ireland cardiac foundation.
-
Abionic Launches First Covid-19 Severity Test to Triage Patients Quickly and Accurately
11/26/2020
Abionic SA, a Swiss Medtech firm based in Lausanne, has developed the cSOFA score, a tool to assess the severity of Covid-19.
-
Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference
11/26/2020
Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the Evercore ISI 3 rd Annual HealthCONx conference being held December 1-3, 2020. Conference Presentation Details Conference: Evercore ISI 3 rd
-
Amgen To Present At The Evercore ISI Virtual HealthCONx Conference
11/26/2020
Amgen (NASDAQ:AMGN) will present at the Evercore ISI Virtual HealthCONx Conference at 1:50 p.m. ET on Tuesday , Dec. 1, 2020. David M. Reese , M.D., executive vice president of Research and Development and Peter H. Griffith , executive vice president and chief financial officer at Amgen will present at the conference. Li
-
Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations
11/26/2020
CX-5461 was recently named as a PCF-Pfizer Global Challenge Award recipient.
-
Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome
11/26/2020
MDS is a heterogeneous group of clonal disorders of the bone marrow hematopoietic stem cells (HPSCs), characterized by ineffective hematopoiesis with peripheral blood cytopenia and a higher risk for developing acute myeloid leukemia (AML).
-
Even companies with otherwise promising pipelines or successful products on the market sometimes face clinical trial failures. Two such companies had disappointing clinical trial announcements today.